

REMARKS

The Present Invention

The present invention pertains to cancer peptides consisting of a portion of SEQ ID NO: 4, wherein the portion comprises (i) amino acids 55-62 of SEQ ID NO: 4 or (ii) amino acids 127-136 of SEQ ID NO: 4 and functionally equivalent variants thereof, as well as compositions and immunogens, both of which comprise the cancer peptides.

The Pending Claims

Claims 3, 5-8, 10, 12-15, 26, 28, 29, 67-104 are currently pending, of which claims 3, 5-8, 10, 12-15, 67-77, and 87-98 are directed to isolated cancer peptides, claims 26, 86, and 99 are directed to compositions comprising the cancer peptides, and claims 28, 29, 78-85, 100-104 are directed to immunogens comprising the cancer peptides.

Amendments to the Claims

Claims 11 and 16 have been cancelled. Applicants reserve the right to pursue any canceled subject matter in a continuation, continuation-in-part, divisional, or other application. Cancellation of any subject matter should not be construed as abandonment of that subject matter.

Claim 3 has been amended to recite the limitations of claims 11 and 16. Claim 3 also has been amended to delete the transitional phrase "consisting essentially of." Claim 3 now recites "consisting of a portion of SEQ ID NO: 4." Claim 3 has been further amended to recite that the antigen of the antigen specific cytotoxic T lymphocytes is an epitope of a protein having the amino acid sequence of SEQ ID NO: 4, which is supported by the specification at, for instance, page 9, lines 2-3. Moreover, claim 3 has been amended to recite that the cancer peptide is about 10 amino acids in length, which is supported by the specification at, for example, page 8, line 28, through page 9, line 3.

Claims 3, 5-8, 10, 12-15, 26, 28, 67-78, and 86 have been amended to recite "isolated" in reference to "cancer peptide." In addition to claim 3, claims 10, 12-15, 69, 72, and 74-77 have been amended to recite "consisting of" in lieu of "consisting essentially of." Claims 16 and 28 have been amended to correct claim dependencies, in view of the cancellation of claims 11 and 16.

Claims 87-104 have been added. Claim 87 is supported by the specification at, for instance, page 8, lines 28, through page 9, line 1. Claims 88-91 are supported by the specification at, for instance, Tables 6 and 7. Claims 92-95 are supported by the specification at, for example, page 12, lines 22-26. Claims 96 and 97 are supported by the specification at,

for instance, page 8, lines 9-14. Claim 98 is supported by the specification at, for example page 11, lines 3 and 4. Claims 100-104 are supported by the specification at, for instance, original claims 30 and 31, and page 14, lines 3-17. No new matter has been added by way of these amendments.

Conclusion

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,


John Kilyk, Jr., Reg. No. 30,763
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: January 8, 2004

M:\Clients\nih\amd\218791am3 - supp amd.doc